Canadian grants & funding programs

Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)

The purpose of this funding opportunity is to reduce health disparities through the development and translation of appropriate medical technologies. The NIH defines health disparities as differences in the incidence, prevalence, morbidity, mortality, and burden of diseases and other adverse health outcomes that exist among specific population groups. These population groups include racial and ethnic minorities (African Americans, American Indians, Alaska Natives, Asian Americans, Hispanic Americans, Native Hawaiians, and other U.S. Pacific Islanders, as well as subpopulations of all of these racial/ethnic groups), socioeconomically disadvantaged individuals, sexual and gender minorities, and medically underserved populations including individuals residing in rural and urban areas (see https://www.nimhd/nih.gov/about/overview/). This program seeks advances in medical technologies to reduce health disparities associated with diseases, illnesses, and conditions of public health importance. This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. Proposed medical technologies must have the following basic characteristics: effective, affordable, culturally acceptable, and easily accessible to those who need them. Responsive grant applications will involve a formal collaboration with a healthcare organization or public health agency serving one or more populations that experience health disparities.

United States

NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

Reissue of RFA-MH-20-525. The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.

United States

Green Freight Program: Stream 1 (Assess and Retrofit)

50% funding for fleet energy assessments and truck/trailer fuel-saving retrofits

Grant Goals - Increase knowledge and capacity in on-road freight transportation sector - Support energy efficiency measures tailored to operational needs - Provide financial incentives for fleet optimization and technological retrofits - Promote sustainable transportation infrastructure - Reduce carbon emissions in commercial transportation Keywords - Green freight - Fleet energy assessment - Transportation decarbonization - Fuel efficiency - Aerodynamic retrofits - Anti-idling technologies - Sustainable logistics - Commercial vehicle optimization - Energy-efficient transportation - Emissions reduction - Telematics - Fleet management - Truck technology - Operational efficiency - Sustainable mobility Description The Green Freight Program Stream 1 provides grant funding to support energy efficiency in the commercial transportation sector. The program offers financial assistance for fleet energy assessments and truck/trailer equipment retrofits, targeting organizations operating heavy-duty vehicles in Canada. Target Audience - Transportation companies - Fleet operators - Logistics organizations - Industry associations - Research associations - Indigenous and community groups - Academic institutions - Provincial/territorial/municipal governments - Commercial vehicle owners Eligible Expenses - Third-party fleet energy assessments - Aerodynamic retrofits - Anti-idling technologies - Auxiliary power units - Tire technologies - Telematics devices - Installation costs for approved devices Eligibility - Entities operating in Canada - Organizations with heavy-duty vehicles licensed in Canada - Vehicles between Class 2B and Class 8 weight ratings - Commercial cargo vans and off-road vehicles - Leased vehicles with valid agreements Criteria - Vehicles must be in active service - Registered and insured in Canada - Meet specific weight class requirements - Retrofits completed after December 12, 2022 - Fleet energy assessment required before device purchase Program Requirements - Maximum grant of $250,000 per applicant per fiscal year - 50% funding for most retrofit devices - Continuous intake until March 31, 2027 - Online application through dedicated portal - Comprehensive documentation submission - Compliance with NRCan assessment guidelines Hiring Criteria - Third-party energy assessment companies - Installation service providers - Must meet NRCan's assessment criteria - Demonstrated expertise in fleet efficiency - Ability to provide detailed technological recommendations Due Dates - Continuous intake until March 31, 2027 - Fiscal year: April 1 to March 31 - Application review within 5 business days Start Dates - Retrofits eligible from December 12, 2022 - Ongoing program with annual updates - Fiscal year funding allocation Age Requirements - No specific age restrictions - Applicable to organizations and commercial entities Industry / Area of Work - Transportation and logistics - Commercial freight - Sustainable mobility - Energy efficiency - Fleet management - Trucking and commercial vehicle sectors

Alberta · British Columbia · Manitoba · New Brunswick +9 more

Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)

This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS.

United States

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across NHGRIs scientific areas and will incorporate a plan for strategies to facilitate inclusive and diverse perspectives. Applications from New or Early Stage Investigators from diverse backgrounds are encouraged.

United States

Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)

The purpose of this fundng opportunity announcemnt (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.

United States

Opportunities for Advancing Limb Regeneration Research (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to promote transformative basic research on limb regeneration using animal models. The primary focus is on gaining insight into the bodys own growth regulatory networks and processes that can be manipulated to promote limb regeneration in vertebrates including in mammals that might otherwise lack the capacity for regeneration. The overarching goal is to improve human conditions of developmental limb deficiencies and address human limb injury or amputation challenges that can be attained in both near term and long term.

United States

Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed)

The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding ofthe physiologic drivers of T2D subtypes to guide development of more effective precision interventions.

United States

Rural Economic Development program – Strategic Economic Infrastructure Stream

50% funding for economic growth, infrastructure, and community development in rural Ontario.

Ontario’s Rural Economic Development (RED) program provides cost-share funding to support activities that create strong rural communities in Ontario

Ontario

Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This funding opportunity will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

United States

Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)

"This FOA will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following:. - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD).. - Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic).. - Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD)."

United States

In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

United States

National Organizations of State and Local Officials: State Health Services and Financing

This notice announces the opportunity to apply for funding under the National Organizations of State and Local Officials (NOSLO) Program: State Health Services and Financing to fund a national level organization with an in-depth understanding of, and experience with, providing technical assistance and support to State Medicaid Directors and other health care payment officials.. The purpose of the NOSLO program is to assist state and local authorities in a) improving public health, health care and health care delivery, b) building capacity to address public health issues and support and enforce regulations intended to improve the public‚Äôs health, and c) promoting health equity to preserve and improve public health. To fulfill the purpose, the NOSLO program has the following objectives: 1) facilitate communication and data/information-sharing between HRSA and state, territorial, and/or local officials, 2) improve understanding of state, territorial, and/or local needs, priorities, and perspectives, and 3) support capacity-building activities at the state, territorial, and/or local levels that strengthen the health care safety net and advance public health goals. The term ‚Äúcapacity-building‚Äů includes actions that build, strengthen, and maintain the necessary competencies and resources to improve health services delivery to people who are geographically isolated and/or economically or medically vulnerable.. The NOSLO: State Health Services and Financing cooperative agreement assists states in leveraging HRSA programs and collaborating with Medicaid, including initiatives, models, and data strategies, to improve access to quality health care for people who are medically and economically vulnerable, with a special emphasis on maternal health disparities, geographically isolated people in rural areas, health care needs of people leaving the criminal justice system, individuals with HIV, people with unmet behavioral health needs, including youth, and the health care workforce. The successful recipient is expected to provide tailored technical assistance to State Medicaid Directors and other health care payment officials to address HRSA‚Äôs priorities through:. ‚Ģ Communication and information sharing between HRSA and State Medicaid Directors and other health care payment officials, and. ‚Ģ Training; data collection, sharing, and analysis; publication development; convenings, (e.g., learning exchanges on priority topics); and other activities that enable State Medicaid Directors and other health care payment officials to operate in a responsive, coordinated, and effective manner.. Program Objectives. ‚Ģ Engage multiple states and their State Medicaid Directors and other health care payment officials to develop detailed implementation plans for policy initiatives that will improve access to quality health care for their highest-need populations that intersect with HRSA programs. Where feasible, these initiatives can be shared across multiple states to achieve a nationwide impact.. ‚Ģ Implement technical assistance activities and tools on health care financing policies, models, and data strategies that will improve access to quality health care to address the following: maternal health needs, access to mental health and substance abuse disorder services, health care workforce, healthcare needs of people leaving the criminal justice system, individuals with HIV, and other vulnerable people.. For more details, see Program Requirements and Expectations.

United States

Ontario Creates IDM Fund – Production

Up to 50% of eligible production costs, to a maximum of $250,000.

Support for the production of market-ready interactive digital media products such as games, XR experiences, or interactive attractions content.

Ontario · Canada

Canada Media Fund – Experimental Stream: Prototyping

Up to 75% of eligible costs, to a maximum of $250,000 (typically as a repayable contribution).

Funding to support the development of prototypes for innovative, interactive digital media applications, games, and immersive experiences prior to full production.

Canada

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort.

United States

Study: Retrofit or new construction of sustainable affordable housing

Up to 50% funding for studies, retrofits, and new sustainable affordable housing projects

Grant Goals • Retrofit existing housing and construct energy-efficient affordable homes • Reduce greenhouse gas emissions in residential housing • Lower operating costs for housing providers • Improve housing quality and energy performance • Support sustainable community development Keywords • Sustainable housing • Energy efficiency • Affordable housing retrofit • Green building • Low-carbon housing • Climate resilience • Community housing • Net-zero energy • Residential energy optimization • Social housing innovation • Emissions reduction • Utility cost management • Passive housing design • Renewable energy integration • Housing sustainability • Community infrastructure • Energy performance • Carbon-neutral housing • Affordable housing development • Climate adaptation strategies Description The Sustainable Affordable Housing (SAH) initiative is a $300-million program designed to support not-for-profits, co-ops, and municipalities in transforming residential housing through energy-efficient retrofits and new construction. The program aims to address complex housing challenges by reducing emissions, lowering operating costs, and improving overall housing quality across Canada. Target Audience • Not-for-profit housing organizations • Housing cooperatives • Municipal housing providers • Community housing developers • Social housing administrators • Local government housing departments Eligible Expenses • Energy efficiency upgrades • Retrofit construction costs • Sustainable building materials • Renewable energy system installations • Energy performance assessments • Passive design implementation • Insulation improvements • HVAC system upgrades • Window and door replacements • Structural energy optimization Eligibility • Canadian housing providers • Organizations with existing housing portfolios • Entities focused on affordable housing • Projects demonstrating significant energy performance improvements • Proposals targeting greenhouse gas reduction Criteria • Minimum energy efficiency improvements • Proven sustainability metrics • Financial viability • Community impact assessment • Technical feasibility • Environmental performance standards Program Requirements • Detailed energy performance modeling • Comprehensive sustainability assessment • Greenhouse gas reduction targets • Cost-benefit analysis • Long-term operational efficiency plan Hiring Criteria • Sustainability expertise • Energy engineering skills • Green building certification • Climate adaptation knowledge • Community development experience Due Dates • Capital projects funding: Closed • Planning and study grants: Paused until April 2026 Start Dates • Ongoing program evolution • Renewed focus on early-stage planning • Potential restart in April 2026 Age Requirements • No specific age restrictions • Focus on organizational capacity and project potential Industry / Area of Work • Residential housing • Community infrastructure • Sustainable urban development • Energy efficiency sector • Climate action and resilience • Social housing management

Alberta · British Columbia · Manitoba · New Brunswick +9 more

International Technology Partnership Program - Alberta Innovates

75% funding for product development, pilot tests, and international partnerships.

The program helps Alberta technology businesses further develop their product or pilot the technical and business merits of their product to prove its value, and advance commercialization.

Alberta

Tourism Product Diversification and Marketing Program

75% funding for product development, marketing, and safety upgrades in tourism.

The Tourism Product Diversification and Marketing Program provides funding for business planning, product development, and marketing projects to improve tourism products and operations in the Northwest Territories.

Northwest Territories

Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics. Projects will identify targets for future social network health behavior change interventions across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- to- late life). Basic research to develop, refine, or optimize measures (assays) of putative targets (e.g., intra/interpersonal mechanisms of behavior change and/or social network characteristics) are also supported by this NOFO. . Clinical trials that do not meet the federal definition of basic research (CFR 272.3) are not responsive to this RFA. Projects that propose to support the planning activities necessary to develop social network interventions for which a target has already been identified are most appropriate for the R34 RFA companion (RFA-AG-24-026).

United States

Personal Responsibility Education Program (PREP) Competitive Grants: New Hampshire

The Administration for Children and Families (ACF), Administration on Children, Youth and Families' (ACYF) Family and Youth Services Bureau (FYSB) will be accepting applications from eligible local organizations and entities located in New Hampshire, for the development and implementation of the Personal Responsibility Education Program (PREP) in states that do not accept FY2023 allocations for State PREP. The purpose of this program is to support projects that educate youth, between the ages of 10 and 19 years, and pregnant and parenting youth under age 21, on abstinence and contraception for the prevention of pregnancy, sexually transmitted infections, and HIV/AIDS. Projects are also required to implement at least three of six adulthood preparation subjects.

United States

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

United States

Limited Competition for the Continuation or Revision of Multisite Clinical Trial Clinical Coordinating Center (Collaborative UH3 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications for competing renewal of Clinical Coordinating Center (CCC) for ongoing clinical trials supported by NCCIH; or competitive revisions to support ancillary studies to ongoing NCCIH supported clinical trials. Extension of an ongoing clinical trial will be supported when there is need for additional time to complete the trial or when an extended period of follow up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for the addition of an ancillary study to an ongoing clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Both a DCC application and a corresponding Clinical Coordinating Center application should be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application or competitive revision prior to submitting to this FOA.

United States

Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional)

The purpose of thisNotice of Funding Opportunity (NOFO)is to invite applicationsfocused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this NOFO.

United States

Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)

Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

United States

Tourism Growth Program - Quebec

The Tourism Growth Program (TGP) aims to enhance tourism products and experiences in Quebec to attract visitors from outside the province, focusing on rural and remote regions. Eligible activities include increasing tourism spin-offs in communities, supporting Indigenous tourism, developing sustainable tourism experiences, and extending the tourism season. The program offers financial contributions ranging from over $60,000 to $250,000, with a portion of the funds dedicated to Indigenous tourism initiatives.

Canada

Northern Indigenous Economic Opportunities Economic – Research Stream

I couldn't find specific funding percentages or eligible expenses directly related to the grant from the provided webpage. Therefore, I cannot create an accurate tagline based on the grant's actual offerings. If you have more specific details about the grant, please share them, and I can help craft a tagline.

The Economic Research Stream (ERS) is one of three contribution streams of the Northern Indigenous Economic Opportunities Program (NIEOP). ERS works to strengthen the territorial Indigenous business space through economic research and knowledge development. The purpose of ERS is to Address knowledge gaps in the territorial Indigenous economic ecosystem through knowledge, research and statistics. Maximize economic opportunities and prosperity for Indigenous community-owned businesses, private Indigenous businesses and Indigenous entrepreneurs.

Canada

Limited Competition for the Continuation of Multisite Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials supported by NCCIH. Extension of an ongoing clinical trial will be supported when there is need for additional time to complete the trial or when an extended period of follow up is well justified to assess longer term outcomes. The DCC competing renewal application must propose a comprehensive plan for completion of the clinical trial data collection that provides overall project coordination and administrative; data management; and biostatistical support for the ongoing clinical trial. Both a DCC application and a corresponding Clinical Coordinating Center application can be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing. If clinical trial data collection and follow up can be completed centrally by the DCC and no study visits at clinical sites are needed, a single application for competing renewal for the DCC can be submitted. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application prior to submitting to this FOA.

United States

Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)

Reissue of RFA-MH-19-242.This Funding Opportunity Announcement (FOA) solicits proposals for research projects that will use computational approaches to test the validity of dimensional constructs in the NIMH Research Domain Criteria matrix (or similar constructs based on comparable criteria). Some elements of the RDoC matrix have been updated since its first release, but a thorough data-driven validation that broadly explores, compares, and validates the constructs within the matrix has not been performed. This FOA seeks research that addresses the following questions: do the different domains of behavior segregate from each other? How much do they rely on distinct vs. overlapping neural circuits? What are the relationships between domains, constructs and subordinate subconstructs, both in terms of their correlational structure and their underlying neural circuitry? By answering these questions, proposals will test integrative models of functioning and identify dysregulation in psychopathology-related mechanisms that may cut across traditional diagnostic categories and may change over time. This FOA seeks to promote projects where the computational and the experimental components are well-integrated. The ultimate goal is to advance translational research that will identify novel classification approaches and/or treatment targets, and lead to more effective and timely interventions for serious mental illness.

United States

The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)

The MetNet is a collection of Research Centers that support using systems level approaches to understand the non-linear, dynamic and emergent processes in metastasis. Considering chronological progression and biological scales, the MetNet seeks to collectively derive a more comprehensive and cohesive picture of metastasis as a whole body, systems-level problem.

United States

Cancer Immunoprevention Network (CIP-Net) ?Research Projects (UG3/UH3 Clinical Trials Not Allowed)

The purpose of the Cancer Immunoprevention Network (CIP-Net) is to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, and foster a community of cancer immunoprevention researchers. ?The UG3/UH3 research projects will enable de novo discovery of immune pathways, immunoprevention mechanisms, or investigation of new vaccine or immunomodulatory targets or agents. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Achievement of the UG3 milestones will be necessary for transition to the UH3 phase. UH3 phase may be awarded after administrative review of the UG3 milestones. Provided these milestones are achieved, UH3 phase may continue.

United States

National Housing Strategy Demonstrations

80% funding for demonstrating innovative housing solutions, research, stakeholder engagement, and scaling impact

Grant Goals - Demonstrate innovative solutions supporting housing affordability - Increase adoption of high-quality housing solutions - Support scaling and replication of innovative housing approaches - Generate new evidence and data for housing sector - Engage stakeholders across diverse geographic, social, and economic contexts Keywords - Housing innovation - Affordable housing solutions - Scalable housing models - Community housing - Urban housing transformation - Modular construction - Retrofit strategies - Social impact housing - Land trust development - Collaborative housing approaches - Sustainable housing design - Adaptive reuse - Community-driven housing - Technology-enabled housing solutions - Inclusive housing strategies Description The National Housing Strategy Demonstrations Initiative funds innovative housing solutions that address Canada's affordable housing challenges. The program supports projects that demonstrate transformative approaches to housing development, focusing on scalability, sustainability, and meaningful impact across diverse community contexts. Target Audience - Community housing providers - Non-profit housing organizations - Affordable housing cooperatives - Government agencies (provincial, territorial, municipal) - Indigenous organizations - Private and non-profit builders/developers - Academic institutions - Innovation hubs - Housing advocacy groups - Social impact organizations Eligible Expenses - Solution development and documentation - Knowledge transfer activities - Collaborative stakeholder engagement - Scaling and adaptation processes - Tools and resource creation - Performance measurement - Capacity building initiatives - Partnership development - Technology implementation - Research and evidence gathering Eligibility - Legally incorporated Canadian organizations - Organizations in good standing with CMHC - No previous breach of CMHC program terms - Canadian-led initiatives with potential for national impact - Projects addressing National Housing Strategy priority groups Criteria - Innovative housing solutions - Evidence of positive impact - Potential for scaling/replication - Clear demonstration objectives - Measurable outcomes - Stakeholder engagement strategy - Alignment with National Housing Strategy goals Program Requirements - Comprehensive project documentation - Knowledge mobilization plan - Stakeholder collaboration framework - Performance tracking methodology - Scalability assessment - Detailed implementation strategy - Ethical research considerations - Alignment with housing sector priorities Hiring Criteria - Expertise in housing innovation - Understanding of community housing dynamics - Technical skills in design/construction - Research and documentation capabilities - Collaborative leadership - Systems thinking approach - Experience with social impact projects Due Dates - Continuous intake process - Specific application windows may vary - Periodic evaluation cycles - Project-specific timelines Start Dates - Flexible project initiation - Alignment with funding approval - Dependent on project readiness - Typically within fiscal year of approval Age Requirements - No specific age restrictions - Focus on organizational capacity - Emphasis on lived experience representation Industry / Area of Work - Affordable housing - Community development - Urban planning - Social innovation - Housing technology - Sustainable design - Non-profit sector - Indigenous housing - Supportive housing - Rental housing development

Alberta · British Columbia · Manitoba · New Brunswick +9 more

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.

United States

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.

United States

Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the measurement and assessment of complex constructs relevant to minority health and health disparities.

United States

Market Readiness Program – Ontario Centre of Innovation (OCI)

75% funding for commercialization, technology development, and market expansion activities.

The Market Readiness Program supports academic spin-off companies, OCI accelerator (CLA/OCIA) graduates, and SmartStart Seed Fund awardees with Ontario government grants to further their early-stage commercialization and support scalable business growth. The program offsets a portion of costs related to customer creation and company-building activities. The funding helps to reduce the risk of other investment opportunities and helps attract additional private investments.

Ontario

Notice of Intent to Publish a Funding Opportunity Announcement for Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to expand the research scope and leverage the gains made through the Ôř?Investigation of the Transmission of KSHVÔř? initiatives (RFA-CA-18-013 and RFA-CA-20-046)Ôř?to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV.. This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The NOFO is expected to use the U01This Notice encourages investigators with expertise and insights into the area of Kaposi sarcoma-associated herpesvirus (KSHV) and/or vaccine development to begin to consider applying for this new NOFO.. Among the areas of research encouraged in this initiative are identification and evaluation of KSHV structural and non-structural targets for a potential KSHV vaccine; development and testing of a candidate KSHV vaccine or vaccines; development of animal models to study a prototype KSHV vaccine or vaccines; studies to assess how the efficacy of a promising KSHV vaccine can be optimized for people with HIV; research to better define the initial steps of infection with KSHV and the primary means of person-to-person transmission in different populations that can be targeted with a vaccine; optimization and/or standardization of KSHV detection methods. In addition, collaborative investigations combining expertise in HIV infection, KSHV infection, immune responses to KSHV and KSHV transmission, virology and vaccine development will be encouraged, and these investigators should also begin considering applying for this NOFO. mechanism with approximately 3-4 awards to be made for each of two receipt dates. Clinical trial is optional. The NOFO is expected to be published in fall of 2023 with expected application due dates in winter of 2023 and 2024. Details of the planned NOFO are provided below.

United States

Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)

This FOA would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream and downstream from aggregated protein states to determine what events lead to worse phenotypic outcomes.

United States

NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-XXX, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

United States

LRCC – Business Grant & Loan Program

50% funding for equipment, marketing, and operating costs to grow your Métis business.

LRCC provides a Business Grant & Loan Program to finance the start-up, acquisition and/or expansion of a Métis-owned small business in Manitoba. Various eligibility requirements and exclusion criteria apply.

Manitoba

Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)?

The purpose of this initiative is to develop measures of financial hardship associated with AD/ADRD that are responsive to the dyadic and family-level financial management arrangements that are common as AD/ADRD progresses. In order to accurately measure financial hardship among people and families living with AD/ADRD, validated screeners are needed to capture unique hardships associated with AD/ADRD that are not measured in screeners developed for people with cancer or in screeners developed for healthy households. This Notice of Funding Opportunity (NOFO) invites research to support the development of measures of financial hardship for persons living with AD/ADRD and their partners, families, or caregivers to facilitate research on financial health-a key social determinant of health- and health related quality of life among older adults with AD/ADRD.

United States

Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)

Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)

United States

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

United States

Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)

The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.

United States

Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

United States

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)

The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement are encouraged.

United States

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

United States

Title V Competitive Sexual Risk Avoidance Education

This Forecast is modified to correct the Estimated Total Funding from $9,000,000 to $4,719,633. The Estimated Post Date and Estimated Application Due Date have remained the same.The purpose of the Competitive SRAE Program is to fund projects to implement sexual risk avoidance education that teach participants how to voluntarily refrain from non-marital sexual activity. Successful applicants are expected to submit plans for the implementation of sexual risk avoidance education that normalizes the optimal health behavior of avoiding non-marital sexual activity, with a focus on the future health, psychological wellbeing, and economic success of youth.  Applicants must agree to: 1) use medically accurate information referenced to peer-reviewed publications by educational, scientific, governmental, or health organizations; implement an evidence-based approach integrating research findings with practical implementation that aligns with the needs and desired outcomes for the intended audience; and 2) teach the benefits associated with self-regulation, success sequencing for poverty prevention, healthy relationships, goal setting, resisting sexual coercion, dating violence, and other youth risk behaviors such as underage drinking or illicit drug use without normalizing teen sexual activity. The Title V SRAE legislation requires unambiguous and primary emphasis and context for each of the A-F topics listed in the NOFO to be addressed in program implementation. Additionally, there is a requirement that messages to youth normalize the optimal health behavior of avoiding non-marital sexual activity.

United States